Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2012 18:38 ET | Source: Novartis Pharma AG

Novartis confident in safety and efficacy of its seasonal influenza vaccines produced in Italy

As precaution, Italian ministry of health temporarily halts distribution of two seasonal influenza vaccines Agrippal and Fluad, produced at Novartis site in Italy Recent clinical trials of these...
October 19, 2012 05:00 ET | Source: Novartis Pharma AG

Inauguration de la nouvelle unité de laboratoires Recherche et Développement / Qualité de Novartis sur le site de Nyon-Prangins

Suite aux annonces qui ont été faites le 17 janvier 2012 pour relancer le site de Nyon-Prangins, le timing est respecté et les projets de développement sont en cours. Dans le cadre de cette...
October 19, 2012 05:00 ET | Source: Novartis Pharma AG

Einweihung des neuen Laborgebäudes für Forschung, Entwicklung und Qualität am Standort Nyon-Prangins

Die Zeitvorgaben für die am 17. Januar 2012 angekündigte Neugestaltung des Standorts Nyon-Prangins werden eingehalten und neue Entwicklungsprojekte gestartet. Im Rahmen dieser neuen...
October 12, 2012 01:15 ET | Source: Novartis Pharma AG

New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months

New analysis of two large Phase III studies demonstrates a significant early treatment effect of Gilenya on relapses and MRI outcomes, including brain volume loss, in MS patients Data show...
October 01, 2012 01:15 ET | Source: Novartis Pharma AG

Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU

Seebri® Breezhaler® 44 mcg delivered dose approved for maintenance treatment of COPD will be available to patients and physicians in some EU markets by year-end In GLOW trials, Seebri® Breezhaler®...
September 27, 2012 02:00 ET | Source: Novartis Pharma AG

Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe plaque psoriasis

Phase II data show AIN457 given weekly during the first month of treatment improved hand/foot psoriasis at Week 12 (54% of patients vs 19% on placebo)[1] AIN457 selectively binds to and...
September 24, 2012 01:15 ET | Source: Novartis Pharma AG

Results from Novartis Phase III study show that RLX030 reduced deaths in patients with acute heart failure

RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and showed RLX030 (serelaxin) was well tolerated[1] Six-month study shows that investigational...
September 21, 2012 08:06 ET | Source: Novartis Pharma AG

Novartis announces two CHMP positive opinions for new indications of Galvus® and Eucreas® combined with other diabetes treatments

Positive opinion for the use of vildagliptin, with or without metformin, in combination with a stable dose of insulin[1] Additional positive opinion for the use of vildagliptin in combination...
September 21, 2012 07:50 ET | Source: Novartis Pharma AG

Novartis drug Votubia® recommended by CHMP for EU approval to treat patients with non-cancerous kidney tumors associated with TSC

Votubia (everolimus) would be the first non-surgical treatment option in the EU for kidney tumors associated with tuberous sclerosis complex (TSC)[1] Kidney tumors, or renal angiomyolipomas,...
September 05, 2012 01:15 ET | Source: Novartis Pharma AG

New data for Novartis drug Lucentis® confirms long-term efficacy and safety profile and benefits of individualized treatment

REPAIR study shows an average of three Lucentis® injections improve visual acuity in patients with myopic choroidal neovascularization RESTORE extension study demonstrates DME patients fully...